Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.

<h4>Background</h4>Her2 expression and amplification occurs in a significant subset of gastro-esophageal carcinomas. Her2 is a client protein of molecular chaperones, e.g. heat shock protein (HSP) 90, rendering targeted therapies against Her2/HSP90 an interesting approach. This study aim...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sabina Berezowska, Alexander Novotny, Karina Bauer, Annette Feuchtinger, Julia Slotta-Huspenina, Karen Becker, Rupert Langer, Axel Walch
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e834074fe05a43dba62b96084fc7a1dc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e834074fe05a43dba62b96084fc7a1dc
record_format	dspace
spelling	oai:doaj.org-article:e834074fe05a43dba62b96084fc7a1dc2021-11-18T07:37:47ZAssociation between HSP90 and Her2 in gastric and gastroesophageal carcinomas.1932-620310.1371/journal.pone.0069098https://doaj.org/article/e834074fe05a43dba62b96084fc7a1dc2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23874879/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Her2 expression and amplification occurs in a significant subset of gastro-esophageal carcinomas. Her2 is a client protein of molecular chaperones, e.g. heat shock protein (HSP) 90, rendering targeted therapies against Her2/HSP90 an interesting approach. This study aimed to investigate the role and relationship of Her2 and HSP90 in gastric and gastro-esophageal adenocarcinomas.<h4>Material and methods</h4>Immunohistochemical determination of HSP90 and Her2 expression was performed on 347 primary resected tumors. Her2 amplification was additionally determined by fluorescence in situ hybridization for all cases. Expression and amplification results were correlated with pathologic parameters (UICC pTNM category, tumor grading) and survival.<h4>Results</h4>Elevated Her2 copy numbers were observed in 87 tumors, 21 of them showing amplification. 174 tumors showed Her2 immunoreactivity/expression. HSP 90 immunoreactivity was found in 125 tumors. There was no difference between gastric carcinomas and carcinomas of the gastroesophageal junction regarding Her2 or HSP90. Both high HSP90 and Her2 expression/amplification were associated with earlier tumor stages (p<0.01), absence of lymph node metastases (p<0.02) and Laurens intestinal type (p<0.001). HSP90 correlated with Her2 expression and amplification (p<0.001 each). Expressions of HSP90 and Her2, but not Her2 amplification were associated with better prognosis (p=0.02; p=0.004; p=0.802). Moreover, Her2 expression was an independent prognostic factor for overall survival in the subgroup of gastric carcinoma patients (p=0.014) besides pT category, pN category and distant metastases.<h4>Conclusion</h4>Her2 expression and gene amplification occurred in a significant subset of cases. Our results suggest a favorable prognostic impact of Her2 expression. This warrants further investigations regarding the significance of Her2 non-amplified tumors showing Her2 immunoreactivity and the definition of Her2 status in gastric cancers. Moreover, the correlation of Her2 expression with the expression of Her2 chaperoning HSP90 may indicate a synergistic regulation. Targeting HSP90 with or without Her2 may offer additional therapeutic options for gastric carcinoma treatment.Sabina BerezowskaAlexander NovotnyKarina BauerAnnette FeuchtingerJulia Slotta-HuspeninaKaren BeckerRupert LangerAxel WalchPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 7, p e69098 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sabina Berezowska Alexander Novotny Karina Bauer Annette Feuchtinger Julia Slotta-Huspenina Karen Becker Rupert Langer Axel Walch Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
description	<h4>Background</h4>Her2 expression and amplification occurs in a significant subset of gastro-esophageal carcinomas. Her2 is a client protein of molecular chaperones, e.g. heat shock protein (HSP) 90, rendering targeted therapies against Her2/HSP90 an interesting approach. This study aimed to investigate the role and relationship of Her2 and HSP90 in gastric and gastro-esophageal adenocarcinomas.<h4>Material and methods</h4>Immunohistochemical determination of HSP90 and Her2 expression was performed on 347 primary resected tumors. Her2 amplification was additionally determined by fluorescence in situ hybridization for all cases. Expression and amplification results were correlated with pathologic parameters (UICC pTNM category, tumor grading) and survival.<h4>Results</h4>Elevated Her2 copy numbers were observed in 87 tumors, 21 of them showing amplification. 174 tumors showed Her2 immunoreactivity/expression. HSP 90 immunoreactivity was found in 125 tumors. There was no difference between gastric carcinomas and carcinomas of the gastroesophageal junction regarding Her2 or HSP90. Both high HSP90 and Her2 expression/amplification were associated with earlier tumor stages (p<0.01), absence of lymph node metastases (p<0.02) and Laurens intestinal type (p<0.001). HSP90 correlated with Her2 expression and amplification (p<0.001 each). Expressions of HSP90 and Her2, but not Her2 amplification were associated with better prognosis (p=0.02; p=0.004; p=0.802). Moreover, Her2 expression was an independent prognostic factor for overall survival in the subgroup of gastric carcinoma patients (p=0.014) besides pT category, pN category and distant metastases.<h4>Conclusion</h4>Her2 expression and gene amplification occurred in a significant subset of cases. Our results suggest a favorable prognostic impact of Her2 expression. This warrants further investigations regarding the significance of Her2 non-amplified tumors showing Her2 immunoreactivity and the definition of Her2 status in gastric cancers. Moreover, the correlation of Her2 expression with the expression of Her2 chaperoning HSP90 may indicate a synergistic regulation. Targeting HSP90 with or without Her2 may offer additional therapeutic options for gastric carcinoma treatment.
format	article
author	Sabina Berezowska Alexander Novotny Karina Bauer Annette Feuchtinger Julia Slotta-Huspenina Karen Becker Rupert Langer Axel Walch
author_facet	Sabina Berezowska Alexander Novotny Karina Bauer Annette Feuchtinger Julia Slotta-Huspenina Karen Becker Rupert Langer Axel Walch
author_sort	Sabina Berezowska
title	Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
title_short	Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
title_full	Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
title_fullStr	Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
title_full_unstemmed	Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
title_sort	association between hsp90 and her2 in gastric and gastroesophageal carcinomas.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/e834074fe05a43dba62b96084fc7a1dc
work_keys_str_mv	AT sabinaberezowska associationbetweenhsp90andher2ingastricandgastroesophagealcarcinomas AT alexandernovotny associationbetweenhsp90andher2ingastricandgastroesophagealcarcinomas AT karinabauer associationbetweenhsp90andher2ingastricandgastroesophagealcarcinomas AT annettefeuchtinger associationbetweenhsp90andher2ingastricandgastroesophagealcarcinomas AT juliaslottahuspenina associationbetweenhsp90andher2ingastricandgastroesophagealcarcinomas AT karenbecker associationbetweenhsp90andher2ingastricandgastroesophagealcarcinomas AT rupertlanger associationbetweenhsp90andher2ingastricandgastroesophagealcarcinomas AT axelwalch associationbetweenhsp90andher2ingastricandgastroesophagealcarcinomas
_version_	1718423196301000704

Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.

Ejemplares similares